1 Min Read
Jan 3 (Reuters) - Protalix Biotherapeutics Inc :
* Protalix Biotherapeutics announces positive interim results from phase ii clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis
* Protalix Biotherapeutics Inc- "We are looking forward to reporting full results from study before end of Q1 of 2017."
* Protalix Biotherapeutics Inc- no serious adverse events were reported in interim results from phase II clinical trial of Alidornase Alfa Source text for Eikon: Further company coverage: